Quick Answer
GeoVax Labs, Inc. reported Stockholders Equity of $5.05 million for the year ending 2024.
- GeoVax Labs, Inc. showed a decrease of -12.4% in Stockholders Equity from 2023 to 2024.
- This data is from GeoVax Labs, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2025.
- XBRL data for this metric is available from 2009 to 2024 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $20.65 million | Q2 2021: $19.46 million | Q3 2021: $18.00 million | Q1 2022: $11.35 million | Q2 2022: $27.87 million | Q3 2022: $31.78 million | Q1 2023: $22.87 million | Q2 2023: $17.16 million | Q3 2023: $9.12 million | Q4 2023: $5.76 million | Q1 2024: $54.3 thousand | Q2 2024: -$2.31 million | Q3 2024: $8.50 million | Q4 2024: $5.05 million | Q1 2025: $7.90 million | Q2 2025: $2.82 million | Q3 2025: $4.91 million.
- Over the full 16 years of available data (2009 to 2024), GeoVax Labs, Inc.'s Stockholders Equity has grown by 34.8%.
- Historical annual values: Fiscal year 2024: $5.05 million | Fiscal year 2023: $5.76 million | Fiscal year 2022: $26.60 million | Fiscal year 2021: $4.36 million | Fiscal year 2020: $9.57 million | Fiscal year 2019: -$1.57 million | Fiscal year 2018: -$1.02 million | Fiscal year 2017: -$321.1 thousand | Fiscal year 2016: $240.4 thousand | Fiscal year 2015: $1.20 million | Fiscal year 2014: $1.15 million | Fiscal year 2013: $2.53 million | Fiscal year 2012: $1.15 million | Fiscal year 2011: $703.6 thousand | Fiscal year 2010: $1.84 million | Fiscal year 2009: $3.74 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: